160 related articles for article (PubMed ID: 3467654)
21. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
23. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
[TBL] [Abstract][Full Text] [Related]
24. [A basic and clinical study of CA 19-9-MP-Mitsui kit for determination of CA 19-9].
Ishii M; Iida M; Seino Y
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2779-86. PubMed ID: 7993114
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
26. [The diagnostic information value of determining tumor-associated antigen Ca-19-9 in pancreatic cancer].
Samoĭlenko VM; Afrikian MN; Itin AB
Vopr Onkol; 1989; 35(9):1050-3. PubMed ID: 2815692
[TBL] [Abstract][Full Text] [Related]
27. [Basic and clinical evaluation of measurement of pancreatic cancer associated antigen, SPan-1].
Chung YS; Nakata B; Tanaka H; Kubo T; Satake K; Sowa M; Umeyama K
Nihon Geka Gakkai Zasshi; 1990 Feb; 91(2):228-33. PubMed ID: 2325607
[TBL] [Abstract][Full Text] [Related]
28. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
[No Abstract] [Full Text] [Related]
29. [A radioimmunometric assay for circulating tumor-associated glycoprotein (TAG-72) using the antigen determinant CA 72-4].
Ohuchi N; Takahashi K; Matoba N; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2761-6. PubMed ID: 2458074
[TBL] [Abstract][Full Text] [Related]
30. [A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
Abe Y; Odagiri E; Jibiki K; Demura R; Demura H
Gan No Rinsho; 1988 Oct; 34(12):1672-6. PubMed ID: 3193612
[TBL] [Abstract][Full Text] [Related]
31. CA 15.3: early results of a new breast cancer marker.
Colomer R; Sole LA; Navarro M; Encabo G; Ruibal A; Salvador L
Anticancer Res; 1986; 6(4):683-4. PubMed ID: 3463242
[TBL] [Abstract][Full Text] [Related]
32. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
33. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
Vindimian M; Lafitte JJ; Wattre P
Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
[TBL] [Abstract][Full Text] [Related]
34. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
35. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit].
Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H
Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025
[TBL] [Abstract][Full Text] [Related]
36. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
[TBL] [Abstract][Full Text] [Related]
37. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
39. [Basic and clinical studies on serum CEA levels using a new CEA-EIA (double monoclonal) kit].
Ogoshi K; Mitomi T
Gan No Rinsho; 1984 Dec; 30(15):1913-8. PubMed ID: 6396422
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of a monoclonal antibody-based enzyme immunoassay (IQ(Bio) PAP-AELIA kit) for prostatic acid phosphatase].
Koshida K; Naito K; Hisazumi H
Hinyokika Kiyo; 1987 Oct; 33(10):1703-7. PubMed ID: 3328502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
